NCT05241392
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 3 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
- Interventions modified
- Secondary endpoints: details revised at 1 of 5 entries
- Publications: details revised at 2 of 2 entries
- Collaborators expanded, about 5 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date changed from estimate of Dec 31, 2024 to Nov 30, 2024
- Study completion date: Dec 31, 2024 to Dec 31, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Dose-escalation phase: A "3+3" dose-escalation design is used to determine MTD \& R2PD. Anti-B7-H3 autologous CAR-T cells were given biweekly to patients at the following doses for each cycle, and 4 cycles as one course. Dose1: 3 patients at a dose of 20 million cells for each cycle. Dose 2: 3 patients at a dose of 60 million cells for each cycle. Dose 3: 3 patients at a dose of 150 million cells for each cycle. Dose 4: 3 patients at a dose of 450 million cells for each cycle. Dose 5: 3 patients at a dose of 900 million cells for each cycle. R2PD confirmation phase: Determine the R2PD based on the results from the previous dose-escalation study; Treat another 12 patients with anti-B7-H3 autologous CAR-T cells biweekly at the R2PD to further confirm the safety of R2PD. At each dose phase, if the patients show tolerate and response to the treatment, these patients would receive several courses of treatment at PI's discretion.
Biologicals: B7-H3-targeting CAR-T cells/TX103-CAR-T Cell Injection
Sites
1 site in 1 country
- Beijing Tiantan HospitalBeijing, Beijing Municipality, China